Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian A Walker

Blood

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Blood|January 22, 2025
Evaluating the impact of CRBN mutations on response to immunomodulatory drugs and novel cereblon E3 ligase modulators in myelomaYakinthi Chrisochoidou, Andrea Scarpino, Salomon Morales, et al.
Blood|May 18, 2006
Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myelomaBrian A Walker, Paola E Leone, Matthew W Jenner, et al.
Blood|October 15, 2010
Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myelomaBrian A Walker, Christopher P Wardell, Laura Chiecchio, et al.
Blood|May 24, 2013
Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myelomaMartin F Kaiser, David C Johnson, Ping Wu, et al.
Blood|February 26, 2013
Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cellsBrian A Walker, Christopher P Wardell, David C Johnson, et al.
Blood|April 28, 2010
XBP1s levels are implicated in the biology and outcome of myeloma mediating different clinical outcomes to thalidomide-based treatmentsTina Bagratuni, Ping Wu, David Gonzalez de Castro, et al.
Blood|May 11, 2012
Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myelomaBrian A Walker, Christopher P Wardell, Lorenzo Melchor, et al.
Blood|August 23, 2017
Neutral tumor evolution in myeloma is associated with poor prognosisDavid C Johnson, Oleg Lenive, Jonathan Mitchell, et al.
Blood|November 28, 2014
Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocationsCharlotte Pawlyn, Lorenzo Melchor, Alex Murison, et al.
Blood|July 10, 2010
A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic valueBrian A Walker, Paola E Leone, Laura Chiecchio, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Blood|January 22, 2025
Evaluating the impact of CRBN mutations on response to immunomodulatory drugs and novel cereblon E3 ligase modulators in myelomaYakinthi Chrisochoidou, Andrea Scarpino, Salomon Morales, et al.
Blood|May 18, 2006
Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myelomaBrian A Walker, Paola E Leone, Matthew W Jenner, et al.
Blood|October 15, 2010
Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myelomaBrian A Walker, Christopher P Wardell, Laura Chiecchio, et al.
Blood|May 24, 2013
Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myelomaMartin F Kaiser, David C Johnson, Ping Wu, et al.
Blood|February 26, 2013
Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cellsBrian A Walker, Christopher P Wardell, David C Johnson, et al.
Blood|April 28, 2010
XBP1s levels are implicated in the biology and outcome of myeloma mediating different clinical outcomes to thalidomide-based treatmentsTina Bagratuni, Ping Wu, David Gonzalez de Castro, et al.
Blood|May 11, 2012
Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myelomaBrian A Walker, Christopher P Wardell, Lorenzo Melchor, et al.
Blood|August 23, 2017
Neutral tumor evolution in myeloma is associated with poor prognosisDavid C Johnson, Oleg Lenive, Jonathan Mitchell, et al.
Blood|November 28, 2014
Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocationsCharlotte Pawlyn, Lorenzo Melchor, Alex Murison, et al.
Blood|July 10, 2010
A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic valueBrian A Walker, Paola E Leone, Laura Chiecchio, et al.
Pageof 2